Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045936 | 0.83 | EGFR (0.53) | KCNN3MAPTKMT2AMEN1EGFR | |
| SCHEMBL6024935 | 0.77 | APP (0.59) | MAPTAPP | |
| SCHEMBL13219674 | 0.74 | TSHR (0.66) | MAPTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL4014057 | 0.72 | EGFR (0.57) | KCNN3MAPTKMT2AMEN1EGFR | |
| SCHEMBL13623067 | 0.71 | ALDH1A1 (0.61) | MAPTKMT2AMEN1EGFRALDH1A1 | |
| SCHEMBL7500783 | 0.71 | TSHR (0.54) | KCNN3MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL1829879 | 0.71 | TSHR (0.61) | MAPTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL17201936 | 0.71 | EGFR (0.53) | KCNN3MAPTKMT2AMEN1EGFR | |
| SCHEMBL6153829 | 0.70 | MAPT (0.63) | KCNN3MAPTKMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1075280 | 0.70 | ALDH1A1 (0.60) | MAPTKMT2AMEN1EGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | KCNN3 796/4885MAPT 769/4885KMT2A 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.